Stroke

BCV Campbell; P Khatri

Journal article

Stroke

BCV Campbell, P Khatri

Lancet | ELSEVIER SCIENCE INC | Published : 2020

DOI: 10.1016/S0140-6736(20)31179-X

Abstract

Stroke is a major cause of death and disability globally. Diagnosis depends on clinical features and brain imaging to differentiate between ischaemic stroke and intracerebral haemorrhage. Non-contrast CT can exclude haemorrhage, but the addition of CT perfusion imaging and angiography allows a positive diagnosis of ischaemic stroke versus mimics and can identify a large vessel occlusion target for endovascular thrombectomy. Management of ischaemic stroke has greatly advanced, with rapid reperfusion by use of intravenous thrombolysis and endovascular thrombectomy shown to reduce disability. These therapies can now be applied in selected patients who present late to medical care if there is im..

View full abstract

University of Melbourne Researchers

Bruce Campbell Author

Related Projects (4)

EXTEND-IA randomized trial of intra-arterial clot retrieval in ischemic stroke

Most strokes are caused by a blocked blood vessel in the brain. Current treatments to dissolve the blockage improve recovery for many patien..

STROKE IMAGING - IMPROVING PATIENT SELECTION FOR TREATMENT

Stroke is a major cause of death and disability in our community and is most often due to a blocked blood vessel. Powerful treatments are av..

OPTIMIZING STROKE THERAPY - ADVANCED BRAIN IMAGING AND REPERFUSION THERAPIES

Most stroke is due to a blocked blood vessel reducing blood flow to the brain. This research aims to optimize fast restoration of blood flow..

SAVING BRAIN AND CHANGING PRACTICE IN STROKE

Stroke outcomes directly relate to brain tissue rescue. We have contributed to changes in clinical practice through many clinical trials of ..

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

BCVC declares grants from the National Health and Medical Research Council of Australia (1043242, 1035688, 1113352, 1111972) and National Heart Foundation of Australia (100782). PK declares grants from the National Institutes of Health, Nervive, and Cerenovus to her department, and payments to her department from Bayer and Genentech for her role as principal investigator for clinical trials.